Neurophet, a leading artificial intelligence (AI) company specializing in brain disease diagnosis and treatment, announced on Thursday that it has signed a Memorandum of Understanding (MOU) with the Alzheimer’s Network for Treatment and Diagnostic Excellence (ALZ-NET) in the U.S.
This partnership aims to support healthcare professionals involved with ALZ-NET to improve the quality of care for Alzheimer’s patients. Both organizations will collaborate to raise awareness about the critical importance of monitoring Amyloid-Related Imaging Abnormalities (ARIA).
Furthermore, they plan to explore the implementation of Neurophet’s key products in medical institutions participating in ALZ-NET and expand their clinical applications.
The collaboration will leverage several of Neurophet’s flagship solutions, including Neurophet AQUA, a software for analyzing brain neurodegeneration imaging; Neurophet SCALE PET, a quantitative analysis software for Positron Emission Tomography (PET) imaging; and Neurophet AQUA AD Plus, a comprehensive brain imaging analysis solution for Alzheimer’s treatment prescriptions.
Notably, Neurophet AQUA, Neurophet SCALE PET, and Neurophet AQUA AD Plus have all received 510(k) Clearance from the U.S. Food and Drug Administration (FDA). This approval is expected to facilitate the adoption of Neurophet’s key products by numerous Alzheimer’s treatment centers and neuroimaging facilities participating in ALZ-NET.
Bin Jun-gil, co-Chief Executive Officer (CEO) of Neurophet, expressed his enthusiasm about the agreement, stating that this partnership represents a significant milestone for Neurophet as it contributes to establishing crucial imaging-based monitoring infrastructure for the new era of Alzheimer’s treatment. It is committed to working closely with ALZ-NET to elevate the quality of Alzheimer’s care across the U.S.
